Dr AlHilali Consultant Clinical Oncologist
All articles
Pancreatic cancer Understanding treatment

Daraxonrasib for pancreatic cancer: understanding the survival results

What the RASolute 302 pancreatic-cancer results compared, what median survival means, and why trial results do not guarantee an individual's outcome.

Written and clinically reviewed by Dr AlHilali Consultant Clinical Oncologist

Published Clinical review

Daraxonrasib is an oral medicine that targets active RAS proteins, part of the signalling machinery that can help cancer cells grow. Its pancreatic-cancer trial results deserve attention, but “doubled survival” needs a careful explanation.

The result describes groups of people in a particular trial. It does not mean that a tablet doubles every patient's remaining life or cures pancreatic cancer.

In this article

Who took part, and what was compared?

RASolute 302 compared daraxonrasib with selected standard chemotherapy in people with previously treated metastatic pancreatic ductal adenocarcinoma. Metastatic means the cancer had spread to distant parts of the body.

This is a particular type and setting of pancreatic cancer. It is not a study of every pancreatic tumour, treatment before surgery, or a universal replacement for initial chemotherapy. The operability article explains why these distinctions matter.

Pink and purple H&E-stained microscopic section of pancreatic adenocarcinoma.
A histological example of pancreatic adenocarcinoma, stained with haematoxylin and eosin. It is not from the daraxonrasib trial and does not show treatment response or RAS status. Full field retained; resized without enlargement and compressed. Micrograph: KGH. Source · CC BY-SA 3.0

What does 13.2 versus 6.7 months mean?

The sponsor reported median overall survival of 13.2 months with daraxonrasib and 6.7 months with chemotherapy in the overall trial population. These are medians measured from the trial's starting point, not from the first symptom or original diagnosis.

A median is a midpoint in a group's survival experience. Some people live longer and others less long. The ratio between two medians is not a personal prediction. Confidence intervals, follow-up and the full survival curves also matter.

See what a prognosis can and cannot tell you for more context.

A tablet can still cause significant side effects

Oral treatment is not automatically mild. The October 2026 sponsor report lists important risks and adverse effects, including skin and mouth problems and diarrhoea. Suitability depends on the full clinical picture, other medicines and appropriate monitoring.

The detailed evidence should include quality of life, tolerability and how often treatment was stopped, not only the headline survival result.

Does a positive result mean I can receive it now?

Trial results, licensing in a particular country and local funding are different questions. A US approval does not by itself establish NHS availability. Current UK access needs to be checked with the treating team rather than inferred from a news report.

Ask whether the evidence fits your diagnosis and previous treatment, what options are available locally, and whether a suitable clinical trial is open. General information only; this article cannot recommend a treatment for an individual.

Sources

Continue reading